Cognition Therapeutics INC (CGTX) — SEC Filings

Overview

Cognition Therapeutics INC (CGTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-8 filed on Mar 26, 2026: COGNITION THERAPEUTICS INC (CIK: 0001455365) filed an S-8 on March 26, 2026, to register securities for its employee benefit plans. This filing, with File No. 333-294619, allows the company to issue shares to employees, which can dilute existing shareholder value if new shares are created, but also

Sentiment Summary

Across 43 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 38 neutral, 1 mixed. The dominant filing sentiment for Cognition Therapeutics INC is neutral.

Filing Type Overview

Cognition Therapeutics INC (CGTX) has filed 1 S-8, 30 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (43)

• COGNITION THERAPEUTICS Files S-8 for Employee Stock Plans — S-8 · Mar 26, 2026
  COGNITION THERAPEUTICS INC (CIK: 0001455365) filed an S-8 on March 26, 2026, to register securities for its employee benefit plans. This filing, with File No. 3
• COGNITION THERAPEUTICS Files 8-K on Financial Results — 8-K · Mar 26, 2026
  COGNITION THERAPEUTICS INC filed an 8-K on March 26, 2026, disclosing results of operations and financial condition under Item 2.02 and Regulation FD Disclosure
• 8-K Filing — 8-K · Dec 18, 2025
• Cognition Therapeutics Narrows Loss, Boosts Cash with $27.9M Offering — 10-Q · Nov 6, 2025 Risk: high
  Cognition Therapeutics Inc. (CGTX) reported a net loss of $4.93 million for the three months ended September 30, 2025, a significant improvement from the $9.94
• 8-K Filing — 8-K · Sep 15, 2025
• Cognition Therapeutics Enters Material Definitive Agreement — 8-K · Aug 28, 2025 Risk: medium
  Cognition Therapeutics, Inc. announced on August 27, 2025, that it entered into a material definitive agreement. The filing does not provide specific details ab
• Cognition Therapeutics Files 8-K — 8-K · Aug 26, 2025 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on August 26, 2025, reporting an event under "Other Events." The filing does not contain specific details about the ev
• Cognition Therapeutics Files 8-K on Financials — 8-K · Aug 7, 2025 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition, and including financial statements
• Cognition Therapeutics Fuels R&D with $5.1M Equity Raise — 10-Q · Aug 7, 2025 Risk: high
  COGNITION THERAPEUTICS INC (CGTX) reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage biotechnology status.
• Cognition Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 20, 2025 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on June 20, 2025, reporting on matters submitted to a vote of security holders as of June 18, 2025. The filing does no
• Cognition Therapeutics Files 8-K — 8-K · Jun 3, 2025 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on June 3, 2025, reporting other events and financial statements. The filing details the company's principal executive
• 8-K Filing — 8-K · Jun 2, 2025
• Cognition Therapeutics Files 8-K — 8-K · May 8, 2025 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on May 8, 2025, reporting other events and financial statements. The filing does not contain specific financial figure
• Cognition Therapeutics Files 8-K on Financials — 8-K · May 7, 2025 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition, and including financial statements and
• Cognition Therapeutics Q1 2025 Financial Update — 10-Q · May 7, 2025 Risk: medium
  Cognition Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported $59,854,877 in Additional Paid-In Capital for the first q
• Cognition Therapeutics Files Definitive Proxy Statement — DEF 14A · Apr 28, 2025 Risk: low
  Cognition Therapeutics Inc. filed its definitive proxy statement (DEF 14A) on April 28, 2025, for its annual meeting on June 18, 2025. The filing outlines the c
• Cognition Therapeutics Files 8-K on Financials — 8-K · Mar 20, 2025 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on March 20, 2025, reporting on its results of operations and financial condition. The filing also includes financial
• Cognition Therapeutics Files 2024 10-K — 10-K · Mar 20, 2025 Risk: medium
  Cognition Therapeutics Inc. filed its 2024 10-K on March 20, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company
• Cognition Therapeutics Files 8-K — 8-K · Mar 12, 2025 Risk: medium
  Cognition Therapeutics, Inc. filed an 8-K on March 12, 2025, reporting other events. The filing does not contain specific details about the nature of these even
• Cognition Therapeutics Files 8-K — 8-K · Feb 26, 2025 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on February 26, 2025, reporting on other events and financial statements. The filing does not contain specific financi
• Cognition Therapeutics Files 8-K — 8-K · Jan 28, 2025 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on January 28, 2025, reporting other events and financial statements/exhibits. The filing does not contain specific fi
• Cognition Therapeutics Files 8-K — 8-K · Jan 13, 2025 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
• Cognition Therapeutics Files 8-K — 8-K · Dec 18, 2024 Risk: medium
  Cognition Therapeutics, Inc. filed an 8-K on December 18, 2024, to report other events and financial statements. The filing does not contain specific details ab
• Cognition Therapeutics Files 8-K on Financials — 8-K · Nov 13, 2024 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition, as well as financial statements
• Cognition Therapeutics Q3 2024 Update — 10-Q · Nov 13, 2024 Risk: medium
  Cognition Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $32,165,478 and total liabilities of $
• Cognition Therapeutics Files 8-K — 8-K · Oct 1, 2024 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on October 1, 2024, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD di
• Cognition Therapeutics Faces Delisting Concerns — 8-K · Sep 13, 2024 Risk: high
  Cognition Therapeutics, Inc. filed an 8-K on September 13, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company's p
• Cognition Therapeutics Files 8-K — 8-K · Aug 28, 2024 Risk: medium
  Cognition Therapeutics, Inc. filed an 8-K on August 28, 2024, to report on financial statements and exhibits, and for a Regulation FD Disclosure. The filing doe
• Cognition Therapeutics Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing includes financial state
• Cognition Therapeutics Q2 2024 10-Q Filed — 10-Q · Aug 8, 2024 Risk: medium
  Cognition Therapeutics Inc. filed a 10-Q for the period ending June 30, 2024. The company reported total assets of $32,165,478 and total liabilities of $40,112,
• Cognition Therapeutics Files 8-K — 8-K · Jul 29, 2024 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on July 29, 2024, reporting other events and financial statements. The filing does not contain specific details on new
• Cognition Therapeutics Files 8-K on Security Holder Votes — 8-K · Jun 7, 2024 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on June 7, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specifi
• Cognition Therapeutics Files 8-K on Financials — 8-K · May 7, 2024 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on May 7, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
• Cognition Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: low
  COGNITION THERAPEUTICS INC (CGTX) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Cognition Therapeutics Inc. filed a 10-Q report for the period en
• Cognition Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 26, 2024 Risk: low
  COGNITION THERAPEUTICS INC (CGTX) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Cognition Therapeutics, Inc. will hold its 2024 Annual Meeti
• Cognition Therapeutics Files 8-K — 8-K · Mar 26, 2024 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on March 26, 2024, reporting on its results of operations and financial condition, and including financial statements
• Cognition Therapeutics Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 26, 2024 Risk: medium
  COGNITION THERAPEUTICS INC (CGTX) filed a Annual Report (10-K) with the SEC on March 26, 2024. Cognition Therapeutics Inc. filed its 10-K report for the fiscal
• Cognition Therapeutics Enters Material Definitive Agreement — 8-K · Mar 13, 2024 Risk: medium
  Cognition Therapeutics, Inc. announced on March 11, 2024, that it entered into a Material Definitive Agreement. The company, incorporated in Delaware with its p
• Cognition Therapeutics Files 8-K — 8-K · Mar 11, 2024 Risk: low
  Cognition Therapeutics, Inc. filed an 8-K on March 11, 2024, reporting on its results of operations and financial condition. The filing does not contain specifi
• Cognition Therapeutics Reports Officer Changes and Compensation Arrangements — 8-K · Feb 20, 2024 Risk: medium
  Cognition Therapeutics, Inc. filed an 8-K on February 20, 2024, reporting an event that occurred on February 15, 2024. The filing pertains to the departure or e
• AIGH Capital Management Discloses 5.9% Stake in Cognition Therapeutics — SC 13G/A · Feb 7, 2024
  AIGH Capital Management, LLC, a Maryland-based entity, filed an amended Schedule 13G/A on February 7, 2024, disclosing its beneficial ownership in Cognition The
• Pathstone Family Office Discloses 1M Share Stake in Cognition Therapeutics — SC 13G · Jan 19, 2024
  Pathstone Family Office, LLC, a Delaware-organized entity, reported beneficial ownership of 1,000,000 shares of Cognition Therapeutics Inc. (CGTX) common stock
• Cognition Therapeutics Files Routine 8-K on Jan 4, 2024 — 8-K · Jan 4, 2024
  Cognition Therapeutics, Inc. filed an 8-K on January 4, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing is a routine update,

Risk Profile

Risk Assessment: Of CGTX's 35 recent filings, 3 were flagged as high-risk, 11 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Cognition Therapeutics INC's most recent 10-Q filing (Nov 6, 2025):

• Revenue: $13,407,000
• Net Income: -$20,144,000
• EPS: -$0.30
• Debt-to-Equity: 0.19
• Cash Position: $39,334,000
• Operating Margin: -253.7%
• Total Assets: $43,395,000
• Total Debt: $6,866,000

Key Executives

• Lisa Ricciardi

Industry Context

Cognition Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on age-related degenerative diseases and CNS disorders. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Companies in this space often rely on proprietary technology and strategic financing to advance their pipelines.

Top Tags

8-K (9) · 8-k (7) · financial-reporting (5) · financials (5) · corporate-governance (4) · filing (4) · regulation-fd (3) · Biotechnology (3) · regulatory-filing (3) · SEC Filing (3)

Key Numbers

• Cash and cash equivalents: $39.33M — as of September 30, 2025, up from $25.01M at Dec 31, 2024
• Net loss for nine months: $20.14M — ended September 30, 2025, down from $26.13M in 2024
• Net loss for three months: $4.93M — ended September 30, 2025, down from $9.94M in 2024
• Net proceeds from registered direct offering: $27.89M — in August 2025
• Net proceeds from ATM sales: $8.33M — for the nine months ended September 30, 2025
• Research and development expenses: $26.04M — for the nine months ended September 30, 2025, down from $33.52M in 2024
• Accumulated deficit: $195.30M — as of September 30, 2025
• Common shares outstanding: 88,274,258 — as of November 3, 2025
• SEC File Number: 001-40886 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 13-4365359 — Tax identification number for the company.
• Additional Paid-In Capital increase: $5.1M — from At-Market Offering for the three and six months ended June 30, 2025
• Common Stock increase: $5,108 — from At-Market Offering for the three and six months ended June 30, 2025
• Revenue: 0 — for the three and six months ended June 30, 2025
• Commission File Number: 001-40886 — Identifies the company's SEC filing record.
• I.R.S. Employer Identification No.: 13-4365359 — Company's tax identification number.

Related Companies

COGT · CTXI

Frequently Asked Questions